| Income Statement | 2025-08-31 | |||
|---|---|---|---|---|
| General and administrative | 1,713 | |||
| Research and development | 3,232 | |||
| Total operating expenses | 4,945 | |||
| Operating (loss) gain | -4,945 | |||
| Interest income | 94 | |||
| Interest on convertible notes | 676 | |||
| Finance charges | 13 | |||
| Total interest and other expenses | -595 | |||
| (loss) gain before income taxes | -5,540 | |||
| Income tax benefit | 0 | |||
| Net (loss) income | -5,540 | |||
| Earnings per share, basic | 0 | |||
| Earnings per share, diluted | 0 | |||
| Weighted average number of shares outstanding, basic | 1,252,551,000 | |||
| Weighted average number of shares outstanding, diluted | 1,252,551,000 | |||
CytoDyn Inc. (CYDY)
CytoDyn Inc. (CYDY)